A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Phase 2 Dose Finding Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Anagliptin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2012-02-002409).
- 16 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.